Genome Project News
-
The U.S. Supreme Court restricted the ability of companies to patent human genetic sequences, issuing a mixed ruling in a case that raised questions about thousands of biotechnology, agricultural and drug patents.
-
Sullivan & Cromwell LLP and Latham & Watkins LLP advised Safeway Inc., the second-largest U.S. grocery-store chain, on the sale of its Canadian stores to Empire Co.’s Sobeys Inc. unit for about C$5.8 billion ($5.7 billion) in cash.
-
The U.S. Supreme Court restricted the ability of companies to patent human genetic sequences, issuing a mixed ruling in a case that raised questions about thousands of biotechnology, agricultural and drug patents.
-
The $14.5 billion investment by the U.S. in the Human Genome Project, completed a decade ago, has paid off more than 60-fold in new jobs, drugs and a rapidly expanding genetics industry, an analysis has found.
-
Scientists from research and health- care groups including Harvard University and the U.S. National Institutes of Health are trying to create a way to standardize and share genetic information before the DNA-scanning field develops into a balkanized mess.
-
Almost a decade after the U.S. human genome project was completed, scientists say they have mapped the underlying regulatory system that switches DNA on and off, potentially spurring a wave of new research into the molecular basis of complex diseases such as Type 1 diabetes.
-
Four months after I walked into a lab at Harvard University and gave a vial of blood to have my genome sequenced, my search to understand my DNA led me to Mark Sanders, a former Indiana firefighter.
-
I sat clutching my wife’s hand, nodding, listening, and trying to breathe.
-
On the fourth floor of a red brick medical building in Boston’s South End is an office where few want to go -- where people get a frequently unwelcome glimpse of their future through a careful reading of their DNA.
-
President Barack Obama announced a campaign that could lead to new treatments for some of the least understood brain disorders, benefiting efforts by Pfizer Inc., Roche Holding AG and Eli Lilly & Co.
|
|
Most Popular on Bloomberg
|
| |
Rate this Page